Routes of
administration By mouth Legal status Development terminated PubChem CID 10152654 Route Oral administration | ATC code None CAS Number 603139-19-1 Molar mass 525.56 g/mol | |
 | ||
Synonyms (2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-{[(1S)-2,2,2-trifluoro-1-{4'-(methanesulfonyl)-[1,1'-biphenyl]-4-yl}ethyl]amino}pentanamide | ||
Odanacatib (INN; codenamed MK-0822) is an investigational treatment for osteoporosis and bone metastasis. It is an inhibitor of cathepsin K, an enzyme involved in bone resorption.
It is being developed by Merck & Co. The phase III clinical trial for this compound was stopped early after a review showed it was highly effective and had a good safety profile. Merck announced in 2014 that it would apply for regulatory approval in 2015. In 2014 Cowen and Co predicted odanacatib will generate a billion US$ per year in sales by 2020.
In 2016, Merck discontinued development of odanacatib and announced it would not seek regulatory approval after analysis discovered an increased risk of stroke.
This drug was developed at Merck Frosst in Montreal.
References
Odanacatib Wikipedia(Text) CC BY-SA